WuXi AppTec Repurchases 15.67 Million A-Shares for RMB 732 Million; Hengrui Pharma Presents 78 Oncology Research Abstracts Featuring 14 Innovative Drugs at 2024 ASCO

1. WuXi AppTec Repurchases 15.6653 Million A-shares for Approximately RMB 732 Million

WuXi AppTec Repurchased A-Share Shares Through Centralized Bidding in April 2024, with a Total of 15.6653 Million Shares Repurchased by the End of April, Costing Approximately 732 Million Yuan.

2. 2024 ASCO Preview: Hengrui Pharma's 14 Innovative Drugs with 78 Research Achievements in Oncology Successfully Selected

Hengrui Pharma's 14 innovative drugs achieve 78 research accomplishments in the oncology field, successfully selected for the 2024 ASCO Annual Meeting. These include 8 marketed products and multiple unmarketed ones, covering more than ten cancer treatment areas. Notably, the "Double Ai" combination shows outstanding performance in gastrointestinal tumors, offering new treatment options for global patients and highlighting China's pharmaceutical innovation capabilities.

3. $3 Billion Gene Editing Collaboration Falls Through

Moderna Terminates Gene Editing Collaboration with Metagenomi, Causing Metagenomi's Stock Price to Drop. The collaboration aimed to develop in vivo gene editing therapies but has now been halted. Metagenomi, a biotechnology company with a diversified gene editing toolbox, has received multiple rounds of financing and star capital support, and recently successfully went public on NASDAQ.

4. Buhele Secures Tens of Millions in B-Round Financing for R&D Investment, Capacity Upgrade, and Accelerated Overseas Market Expansion

On May 7, 2024, Qingdao Future Mobile Medical Technology Co., Ltd. completed a Series B financing round worth tens of millions of yuan, with Junxingjian Venture Capital as the investor. This round of financing will be used for R&D investment, production capacity upgrades, and accelerating the layout of overseas markets. The headquarters of Bukele is located in the beautiful coastal city of Qingdao. The company has established R&D and production bases covering 6,000 square meters in both Qingdao and Changsha, and has set up an international business center in Boston, USA. With years of expertise in vibrating mesh nebulization technology, the company is committed to supporting inhalation formulation companies in developing innovative drugs and generic drug-device combination products using vibrating mesh technology, empowering the full lifecycle management of innovative and generic drugs for inhalation formulation enterprises.

5. Jichen Bio Completes Tens of Millions of Yuan in Angel Financing, Building High-Quality Chinese-Manufactured Bioreactors for Biopharmaceuticals

On May 7, 2024, Wuxi Jichen Biotechnology Co., Ltd. completed an angel round of financing worth tens of millions of yuan, led by Daotong Investment and followed by Xichuang Investment Zhiyuan team. This round of financing will mainly be used for new product development, core technology enhancement, product iteration, and the improvement of marketing capabilities and brand influence in domestic and overseas markets. Hou Bin, General Manager of Jichen Biotech, stated: The company will maintain its team philosophy of being cautious from beginning to end, continue to strengthen cooperation with partners, adhere to innovative and breakthrough technological directions, further increase R&D efforts, and continuously launch more competitive products to meet the diverse needs of the market. With the mission of "becoming the most trusted bioreactor expert and pharmaceutical process partner," the company will enhance cooperation and exchanges with enterprises at home and abroad, jointly promoting the advancement and development of the bioreactor industry.

6. Sino Biological Inc. Completes Acquisition of SignalChem Biotech

Sino Biological Inc. Acquires Canadian Biotech Company SCB, Enhancing Its Influence in Recombinant Protein and Technical Service Fields to Provide More Comprehensive Products and Technical Services for Life Science Research, Promoting Innovation and Development in Related Fields.